Outcomes of Preoperative Chemotherapy with Docetaxel, Cisplatin, and 5-Fluorouracil Followed by Esophagectomy in Patients with Resectable Node-Positive Esophageal Cancer

No abstract is available for this paper.

• Publication year

  2014

• Venue

  Annals of Surgical Oncology

• Publication date

  Unknown publication date

• Fields of study

  Not labeled

• Identifiers
  DOI 10.1245/s10434-014-3684-8
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Systematic review and meta‐analysis of the influence of circumferential resection margin involvement on survival in patients with operable oesophageal cancer

  2013cited by this paper
• Comprehensive Registry of Esophageal Cancer in Japan, 2006

  2013cited by this paper
• Significance of Lymph Node Capsular Invasion in Esophageal Squamous Cell Carcinoma

  2012cited by this paper
• Preoperative chemoradiotherapy for esophageal or junctional cancer.

  2012cited by this paper
• Phase II study of docetaxel, cisplatin and 5-fluorouracil (DCF) for metastatic esophageal cancer (OGSG 0403).

  2012cited by this paper
• Multicenter Phase I/II Study of Docetaxel, Cisplatin and Fluorouracil Combination Chemotherapy in Patients with Advanced or Recurrent Squamous Cell Carcinoma of the Esophagus

  2011cited by this paper
• A Randomized Trial Comparing Postoperative Adjuvant Chemotherapy with Cisplatin and 5-Fluorouracil Versus Preoperative Chemotherapy for Localized Advanced Squamous Cell Carcinoma of the Thoracic Esophagus (JCOG9907)

  2011influential reference
• Survival after neoadjuvant chemotherapy or chemoradiotherapy for resectable oesophageal carcinoma: an updated meta-analysis.

  2011cited by this paper
• Induction Chemotherapy with Docetaxel/Cisplatin/5-Fluorouracil for Patients with Node-Positive Esophageal Cancer

  2011cited by this paper
• Phase II study of combined chemotherapy with docetaxel, CDDP and 5-FU for highly advanced esophageal cancer.

  2011cited by this paper
• Phase I/II Study of Docetaxel/Cisplatin/Fluorouracil Combination Chemotherapy Against Metastatic Esophageal Squamous Cell Carcinoma

  2010cited by this paper
• Follow-up and recurrence after a curative esophagectomy for patients with esophageal cancer: the first indicators for recurrence and their prognostic values

  2010cited by this paper
• Esophageal cancer: Clinical Practice Guidelines for diagnosis, treatment and follow-up.

  2010cited by this paper
• Complete pathologic response after neoadjuvant chemoradiotherapy for esophageal cancer is associated with enhanced survival.

  2009influential reference
• A randomized trial of postoperative adjuvant chemotherapy with cisplatin and 5-fluorouracil versus neoadjuvant chemotherapy for clinical stage II/III squamous cell carcinoma of the thoracic esophagus (JCOG 9907)

  2008cited by this paper
• Survival benefits from neoadjuvant chemoradiotherapy or chemotherapy in oesophageal carcinoma: a meta-analysis.

  2007cited by this paper
• Second-Line Combination Chemotherapy with Docetaxel for Cisplatin-Pretreated Refractory Metastatic Esophageal Cancer: A Preliminary Report of Initial Experience

  2007cited by this paper
• Chemoradiation followed by surgery compared with chemoradiation alone in squamous cancer of the esophagus: FFCD 9102.

  2007cited by this paper
• Extranodal Spreading of Esophageal Squamous Cell Carcinoma: Clinicopathological Characteristics and Prognostic Impact

  2007cited by this paper
• Long-term results of RTOG trial 8911 (USA Intergroup 113): a random assignment trial comparison of chemotherapy followed by surgery compared with surgery alone for esophageal cancer.

  2007cited by this paper
• Phase II trial of 5-fluorouracil and low-dose cisplatin in patients with squamous cell carcinoma of the esophagus

  2006cited by this paper
• Comprehensive registry of esophageal cancer in Japan, 1999

  2005cited by this paper
• Chemoradiation with and without surgery in patients with locally advanced squamous cell carcinoma of the esophagus.

  2005cited by this paper
• Surgery alone versus chemoradiotherapy followed by surgery for resectable cancer of the oesophagus: a randomised controlled phase III trial.

  2005cited by this paper
• Surgery plus chemotherapy compared with surgery alone for localized squamous cell carcinoma of the thoracic esophagus: a Japan Clinical Oncology Group Study--JCOG9204.

  2003cited by this paper
• Surgical resection with or without preoperative chemotherapy in oesophageal cancer: a randomised controlled trial.

  2002cited by this paper
• Circumferential resection margin involvement: an independent predictor of survival following surgery for oesophageal cancer

  2001cited by this paper
• New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada.

  2000influential reference
• Induction chemotherapy, surgery, and concomitant chemoradiotherapy for carcinoma of the esophagus: a long-term analysis.

  1998cited by this paper
• TNM Classification of Malignant Tumours

  1987cited by this paper

• Lymph-node ratio as a risk factor for recurrence following neoadjuvant docetaxel, cisplatin, and 5-fluorouracil therapy for locally advanced esophageal squamous cell carcinoma

  2025cites this paper
• Real-world safety and efficacy of neoadjuvant docetaxel, cisplatin, and 5-fluorouracil therapy for locally advanced esophageal squamous cell carcinoma

  2025cites this paper
• The Impact of Worsening Nutritional Status in Neoadjuvant Chemotherapy on Postoperative Outcomes in Esophageal Cancer

  2025cites this paper
• Evaluation of pembrolizumab plus cisplatin and fluorouracil in radical treatment for patients with T4b esophageal squamous cell carcinoma

  2024cites this paper
• Prognosis of patients with residual pathological disease after neoadjuvant docetaxel, cisplatin, and 5-fluorouracil therapy and surgery for esophageal squamous cell carcinoma: a retrospective cohort study

  2024cites this paper
• Microscopic venous invasion is a predictor of prognosis in patients with esophageal squamous cell carcinoma undergoing ineffective neoadjuvant chemotherapy and surgery

  2023cites this paper
• Accurate Preoperative Evaluation of the Location of Esophagogastric Junction Adenocarcinoma Using Positron Emission Tomography–Computed Tomography

  2023cites this paper
• Docetaxel-Based Neoadjuvant Chemotherapy Followed by En Bloc Resection for Esophageal Adenocarcinoma: A 15-Year Retrospective Analysis from a Regional Upper Gastrointestinal Cancer Network

  2023cites this paper
• Total neoadjuvant therapy in oesophageal and gastro-oesophageal junctional adenocarcinoma

  2023cites this paper
• Neoadjuvant Triplet Chemotherapy with Docetaxel, Cisplatin plus 5-Fluorouracil versus Docetaxel, Cisplatin plus S-1 for Advanced Esophageal Squamous cell Carcinoma: Propensity Score Matched Analysis

  2023cites this paper
• Impact of preoperative docetaxel, cisplatin, and 5-fluorouracil (DCF) therapy on degree of malignant esophageal stenosis

  2023cites this paper
• Preoperative docetaxel, cisplatin, and fluorouracil treatment with pegfilgrastim on day 7 for patients with esophageal cancer: A phase II study

  2022cites this paper
• Additional Effects of Docetaxel on Neoadjuvant Radiotherapy With Cisplatin/5-Fluorouracil for Esophageal Squamous Cell Carcinoma

  2022cites this paper
• Current approach in the treatment for resectable esophageal squamous‑cell carcinoma

  2022cites this paper
• Usefulness of Prophylactic Administration of Pegfilgrastim for Esophageal Cancer Chemotherapy: A Single-center Retrospective Study

  2022cites this paper
• Neoadjuvant chemotherapy with S-1 plus cisplatin for esophageal squamous cell carcinoma

  2021cites this paper
• Positron emission tomography complete metabolic response as a favorable prognostic predictor in esophageal cancer following neoadjuvant chemotherapy with docetaxel/cisplatin/5-fluorouracil

  2021cites this paper
• Effects of SLC31A1 and ATP7B polymorphisms on platinum resistance in patients with esophageal squamous cell carcinoma receiving neoadjuvant chemoradiotherapy

  2021cites this paper
• Recent Progress in the Neoadjuvant Treatment Strategy for Locally Advanced Esophageal Cancer

  2021cites this paper
• Five-year Outcomes of Chemotherapy With Docetaxel, Cisplatin, and 5-Fluorouracil Followed by Oesophagectomy in Oesophageal Cancer

  2020cites this paper
• Korean Experiences of the Treatment of Esophageal Squamous Cell Carcinoma

  2020cites this paper
• RAD51 Expression as a Biomarker to Predict Efficacy of Preoperative Therapy and Survival for Esophageal Squamous Cell Carcinoma

  2020cites this paper
• Esophageal Squamous Cell Carcinoma: Diagnosis and Treatment

  2020cites this paper
• Clinical significance of evaluating endoscopic response to neoadjuvant chemotherapy in esophageal squamous cell carcinoma

  2020cites this paper
• Clinical Significance of Prognostic Nutritional Index in the Treatment of Esophageal Squamous Cell Carcinoma

  2020cites this paper
• Neoadjuvant Chemoradiotherapy with Cisplatin Plus Fluorouracil for Borderline Resectable Esophageal Squamous Cell Carcinoma

  2019cites this paper
• The role of pretreatment prognostic nutritional index in esophageal cancer: A meta‐analysis

  2019cites this paper
• The application of neoadjuvant therapy in thoracic esophageal squamous cell carcinoma

  2019cites this paper
• Intratumoral Fusobacterium Nucleatum Levels Predict Therapeutic Response to Neoadjuvant Chemotherapy in Esophageal Squamous Cell Carcinoma

  2019cites this paper
• International Manual of Oncology Practice: iMOP - Principles of Oncology

  2019influential citation
• Long-term complete response in supraclavicular lymph node metastases of esophageal cancer using systemic chemotherapy-a case report.

  2019cites this paper
• Neoadjuvant Chemotherapy with Docetaxel, Cisplatin and S-1 for Resectable Advanced Esophageal Cancer

  2018cites this paper
• Adverse Prognostic Factors of Advanced Esophageal Cancer in Patients Undergoing Induction Therapy with Docetaxel, Cisplatin and 5-Fluorouracil.

  2018cites this paper
• Comparative study of dual energy CT iodine imaging and standardized concentrations before and after chemoradiotherapy for esophageal cancer

  2018cites this paper
• Current Status and Future Prospects for Esophageal Cancer Treatment.

  2017cites this paper
• Current Treatment and Application of Hyperthermia for Squamous Cell Carcinoma of the Esophagus

  2017cites this paper
• Usefulness of computed tomography density of a tumor in predicting the response of advanced esophageal cancer to preoperative chemotherapy

  2017cites this paper
• A 17-molecule set as a predictor of complete response to neoadjuvant chemotherapy with docetaxel, cisplatin, and 5-fluorouracil in esophageal cancer

  2017cites this paper
• Investigation of operative outcomes of thoracoscopic esophagectomy after triplet chemotherapy with docetaxel, cisplatin, and 5-fluorouracil for advanced esophageal squamous cell carcinoma

  2017influential citation
• Surgical Apgar Score Predicted Postoperative Morbidity After Esophagectomy for Esophageal Cancer

  2016cites this paper
• Positive esophageal proximal resection margin: an important prognostic factor for esophageal cancer that warrants adjuvant therapy.

  2016cites this paper
• Expression of BRCA1, a factor closely associated with relapse-free survival, in patients who underwent neoadjuvant chemotherapy with docetaxel, cisplatin, and fluorouracil for squamous cell carcinoma of the esophagus

  2016cites this paper
• Tumor/normal esophagus ratio in 18F-fluorodeoxyglucose positron emission tomography/computed tomography for response and prognosis stratification after neoadjuvant chemotherapy for esophageal squamous cell carcinoma

  2016cites this paper
• Phase II trial of biweekly docetaxel, cisplatin, and 5-fluorouracil chemotherapy for advanced esophageal squamous cell carcinoma

  2016cites this paper
• Phase II trial of neoadjuvant chemotherapy with docetaxel, nedaplatin, and S1 for advanced esophageal squamous cell carcinoma

  2016cites this paper
• The Influence of Neoadjuvant Chemotherapy with Docetaxel, Nedaplatin and 5-Fluorouracil After Esophagectomy.

  2016cites this paper
• Risk factors of early recurrence within 6 months after esophagectomy following neoadjuvant chemotherapy for resectable advanced esophageal squamous cell carcinoma

  2016cites this paper
• Successfully treated advanced esophageal cancer with left axillary lymph node metastasis and synchronous right breast cancer: a case report

  2015cites this paper
• Phase II Study of Docetaxel, Nedaplatin, and 5-Fluorouracil Combined Chemotherapy for Advanced Esophageal Cancer

  2015cites this paper